Susquehanna International Group
INO icon

Susquehanna International Group’s Inovio Pharmaceuticals INO Stock Holding History

Susquehanna International Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$235K Buy
135,100
+94,300
+231% +$155K ﹤0.01% 11389
2025
Q4 		$71K Buy
40,800
+18,000
+79% +$39.6K ﹤0.01% 11621
2025
Q3 		$53.4K Buy
22,800
+9,100
+66% +$17.4K ﹤0.01% 11841
2025
Q2 		$27.9K Buy
+13,700
New +$26.3K ﹤0.01% 12264
2025
Q1 		– Sell
-13,800
Closed -$25.3K – 12947
2024
Q4 		$25.3K Sell
13,800
-79,400
-85% -$351K ﹤0.01% 11875
2024
Q3 		$539K Sell
93,200
-28,800
-24% -$238K ﹤0.01% 8277
2024
Q2 		$986K Sell
122,000
-115,400
-49% -$1.21M ﹤0.01% 6627
2024
Q1 		$3.3M Buy
+237,400
New +$2.05M ﹤0.01% 4336
2023
Q2 		– Sell
-2,958
Closed -$29.1K – 12585
2023
Q1 		$29.1K Sell
2,958
-13,159
-82% -$224K ﹤0.01% 11925
2022
Q4 		$302K Sell
16,117
-4,575
-22% -$104K ﹤0.01% 9081
2022
Q3 		$430K Sell
20,692
-10,066
-33% -$258K ﹤0.01% 8880
2022
Q2 		$639K Sell
30,758
-17,200
-36% -$485K ﹤0.01% 7662
2022
Q1 		$2.07M Sell
47,958
-47,050
-50% -$2.12M ﹤0.01% 5399
2021
Q4 		$5.69M Sell
95,008
-47,000
-33% -$3.77M ﹤0.01% 3523
2021
Q3 		$12.2M Buy
142,008
+25,816
+22% +$2.59M ﹤0.01% 2588
2021
Q2 		$12.9M Buy
116,192
+13,900
+14% +$1.34M ﹤0.01% 2572
2021
Q1 		$11.4M Sell
102,292
-62,308
-38% -$8.19M ﹤0.01% 2580
2020
Q4 		$17.5M Sell
164,600
-2,675
-2% -$356K ﹤0.01% 1884
2020
Q3 		$23.3M Sell
167,275
-18,933
-10% -$3.95M ﹤0.01% 1357
2020
Q2 		$60.2M Buy
186,208
+114,441
+159% +$18.4M 0.01% 727
2020
Q1 		$6.41M Buy
71,767
+69,775
+3,503% +$4.3M ﹤0.01% 2262
2019
Q4 		$79K Buy
+1,992
New +$60K ﹤0.01% 9220
2019
Q3 		– Sell
-2,292
Closed -$81K – 10471
2019
Q2 		$81K Sell
2,292
-158
-6% -$6.28K ﹤0.01% 9694
2019
Q1 		$110K Buy
2,450
+967
+65% +$48.7K ﹤0.01% 8207
2018
Q4 		$71K Sell
1,483
-125
-8% -$7.59K ﹤0.01% 8357
2018
Q3 		$107K Sell
1,608
-3,650
-69% -$203K ﹤0.01% 8580
2018
Q2 		$247K Sell
5,258
-1,792
-25% -$98.8K ﹤0.01% 8217
2018
Q1 		$398K Buy
7,050
+233
+3% +$12.6K ﹤0.01% 7090
2017
Q4 		$338K Sell
6,817
-3,091
-31% -$192K ﹤0.01% 7380
2017
Q3 		$754K Sell
9,908
-3,659
-27% -$272K ﹤0.01% 5792
2017
Q2 		$1.28M Buy
13,567
+5,150
+61% +$440K ﹤0.01% 4761
2017
Q1 		$669K Sell
8,417
-16,358
-66% -$1.3M ﹤0.01% 5951
2016
Q4 		$2.06M Sell
24,775
-2,392
-9% -$216K ﹤0.01% 3995
2016
Q3 		$3.04M Buy
27,167
+1,975
+8% +$218K ﹤0.01% 2880
2016
Q2 		$2.79M Buy
25,192
+2,459
+11% +$299K ﹤0.01% 3035
2016
Q1 		$2.38M Buy
22,733
+1,158
+5% +$89.4K ﹤0.01% 3438
2015
Q4 		$1.74M Sell
21,575
-1,692
-7% -$135K ﹤0.01% 4334
2015
Q3 		$1.61M Buy
23,267
+7,275
+45% +$634K ﹤0.01% 4702
2015
Q2 		$1.57M Buy
15,992
+6,125
+62% +$654K ﹤0.01% 5232
2015
Q1 		$966K Sell
9,867
-5,591
-36% -$542K ﹤0.01% 5836
2014
Q4 		$1.7M Sell
15,458
-1,792
-10% -$219K ﹤0.01% 4759
2014
Q3 		$2.04M Sell
17,250
-23,408
-58% -$2.92M ﹤0.01% 4583
2014
Q2 		$5.27M Buy
+40,658
New +$4.8M ﹤0.01% 2989

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's INO Position: Q1 2026 in Review

Susquehanna International Group reduced its Inovio Pharmaceuticals (INO) stake by 77% in Q1 2026, selling an estimated $319K and leaving 56,862 shares worth $98.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12352.

Susquehanna International Group first reported a position in INO in Q2 2013 and has held it in 45 quarters since. The position peaked at $14.3M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Susquehanna International Group held 56,862 shares of Inovio Pharmaceuticals worth $98.9K as of Q1 2026.
  • Susquehanna International Group sold 194,088 Inovio Pharmaceuticals shares in Q1 2026, an estimated $319K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12352 holding.
  • Susquehanna International Group first reported a position in Inovio Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Inovio Pharmaceuticals position peaked at $14.3M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.